Neumora Therapeutics, Inc.

8-K Other events Jul 27, 2026 8-K Entered a material agreement; Took on a direct financial obligation; Exit or disposal costs; Regulation FD disclosure; Other events Jun 15, 2026 8-K Shareholder vote results May 29, 2026 10-Q Quarter ended 2026-03-31 May 7, 2026 8-K Results of operations (earnings release) May 7, 2026 10-K Fiscal year ended 2025-12-31 Mar 30, 2026 8-K Results of operations (earnings release) Mar 30, 2026 8-K Regulation FD disclosure Feb 11, 2026 8-K Regulation FD disclosure Jan 12, 2026 8-K Other events Jan 5, 2026 8-K Unregistered sale of equity Nov 21, 2025 10-Q Quarter ended 2025-09-30 Nov 6, 2025 8-K Results of operations (earnings release) Nov 6, 2025 8-K Other events Oct 27, 2025 8-K Other events Oct 27, 2025 10-Q Quarter ended 2025-06-30 Aug 6, 2025 8-K Results of operations (earnings release) Aug 6, 2025 8-K Shareholder vote results May 30, 2025 8-K Delisting notice or listing-rule failure May 16, 2025 10-Q Quarter ended 2025-03-31 May 12, 2025 8-K Results of operations (earnings release) May 12, 2025 8-K/A Director or officer change Apr 11, 2025 10-K Fiscal year ended 2024-12-31 Mar 3, 2025 8-K Results of operations (earnings release) Mar 3, 2025 8-K/A Director or officer change Feb 21, 2025 8-K Director or officer change; Regulation FD disclosure Feb 13, 2025 8-K Regulation FD disclosure Jan 13, 2025 8-K Other events Jan 2, 2025 10-Q Quarter ended 2024-09-30 Nov 12, 2024 8-K Results of operations (earnings release) Nov 12, 2024 10-Q Quarter ended 2024-06-30 Aug 6, 2024 8-K Results of operations (earnings release) Aug 6, 2024 8-K Shareholder vote results Jun 14, 2024 10-Q Quarter ended 2024-03-31 May 7, 2024 8-K Results of operations (earnings release) May 7, 2024 8-K Other events Apr 15, 2024 10-K Fiscal year ended 2023-12-31 Mar 7, 2024 8-K Results of operations (earnings release) Mar 7, 2024 8-K Regulation FD disclosure Jan 8, 2024 8-K Other events Nov 28, 2023